House Passes Bills to Expand Access to Low-value, High-deductible Plans

Jul 26, 2018 - 03:50 PM
health-insurance

The House of Representatives last night voted 242-176 to approve legislation (H.R. 6311) that would allow individuals purchasing health insurance in the individual market to purchase a lower value “copper” plan, which could drive more individuals to buy inadequate coverage and increase bad debt for providers. Earlier this month, AHA expressed concern that “challenges already identified of individuals unable to afford care within their deductibles would be exacerbated in even lower value plans.” H.R. 6311 also delays the reimposition of the fee on health insurance providers until 2022 and expands limits on health savings account contributions. The House also approved legislation (H.R. 6199) that would incentivize HSAs, which are paired with high-deductible health plans, by expanding the allowable uses of HSAs; as well as legislation (H.R. 184) to repeal the Affordable Care Act’s medical device tax.
 

Related News Articles

Headline
AHA toolkit includes resources to promote 2026 open enrollment 
The AHA has released a social media toolkit with sample posts and graphics encouraging people to sign up for 2026 health coverage via the Health Insurance…
Headline
Cigna announces new pricing model that would share negotiated discounts with consumers
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
KFF analysis highlights limited physician access in Medicare Advantage plans
A new report from KFF reveals that Medicare Advantage enrollees had access to just 48% of the physicians available to Traditional Medicare beneficiaries in…
Chairperson's File
Chair File: Inside the Shutdown and Other Key 2025 Priorities
Public
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
Report finds launch prices for new drugs are significantly higher, exceed inflation
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
Shutdown continues with no significant progress toward funding deal
The government shutdown is expected to continue into next week as the Senate is expected to adjourn Oct. 23 with no plans to vote this weekend. The chamber Oct…